Business Wire

IL-PRICEFX

16.12.2020 15:32:08 CET | Business Wire | Press release

Share
Pricefx Introduces Velo, The Industry’s First Strategic Large Deal Negotiation Solution

Pricefx , the global leader in cloud-native pricing software, today launched Velo, a unique offering for companies to maximize value on large deal negotiations. Designed to manage the largest transactional relationships in each business, Velo is the industry’s first solution specifically focused on helping sellers to prepare for, and win, profit-maximizing outcomes on large contract negotiations, bids, proposals and sourcing events. Combining a proven deal negotiation methodology with innovative technology for value estimation and leverage optimization, Velo now gives businesses the analytical insights, structured process and workflow automation to negotiate highly customized deals with confidence.

For many large B2B companies, the top 5-10% of their customers make up more than 50% of revenue. The agreements with those customers are essential to the company’s survival. With changes in demand, both buyers and sellers seek to optimize their largest positions as contracts and commitments naturally expire or get adjusted. Buyers often use powerful procurement platforms to optimize their position. With Velo, companies can now equip themselves with an equally powerful package of technology and strategy to maximize value, optimize leverage and negotiate to win.

“Companies have traditionally relied on spreadsheets and manual processes, without collaborative tools, thus leaving potential negotiation power unknown,” said Marcin Cichon, CEO and co-founder at Pricefx. “We are giving businesses a powerful, new way to manage large, complex deals, leveling the playing field in negotiations, and improving outcomes. Tribal wisdom and outdated CPQ technology are no match for the capabilities of Velo.”

“Procurement organizations continue to attack the profit and value positions of their largest suppliers,” said Brian Sharp, Chief Revenue Officer for Profit Velocity. “Category-by-category, sellers face a withering storm of sourcing event approaches with software and services geared toward depleting supplier profits and value. Velo is the first solution to re-balance the playing field so that suppliers can capture their fair share of the value they create for their largest customers.”

Pairing Pricefx ValueEstimator and LargeDealOptimizer modules with the proven methodology from partner Profit Velocity, Velo is a one-of-a-kind strategic software solution to maximize profitability and leverage in large deals. It pairs this software with a proven process-centered methodology, leveraging leading-edge scenario-based negotiation playbooks and a team of negotiation experts who have managed over 400 large complex deals with cumulative recurring revenues exceeding $8 Billion/year across a multitude of industry verticals.

LargeDealOptimizer facilitates the planning of large, complex deals with guidance and contextual information to support the negotiation of monolithic deals in one, central location. It manages deal teams through the workflow of establishing opening positions, anticipating buyer objections and counter-proposals, while aligning the team with their leadership’s objectives and governance. Efficiently streamlining, organizing, and approving complex customer transactions within the Pricefx platform, LargeDealOptimizer enables organizations to get the most value and profit from the customers that generate much of their revenue.

ValueEstimator enables companies to assess their differential competitive value based on the actual customer-based decision drivers. It establishes value-based pricing while enabling that value to be communicated when a price is set for a customer quote or proposal.

Velo provides a proven, immersive and agile service led by world-class negotiation experts, assuring business leaders and P&L owners that each deal team is ready to negotiate-to-win. While every large deal is customized by their very nature, the Velo solution provides a repeatable process-centered approach which fully integrates the new software tools. Early customer reviews of Velo say that Pricefx is offering “a unique new capability that connects its powerful price optimization engine to customer value data. We've waited a long time for this – a huge breakthrough for pricing leaders.”

Velo is easy-to-deploy and can be delivered one deal at-a-time or through a subscription-based approach to support the highest stakes deals. Historically businesses have consistently grown the profitability of their large customer transactions by an average of 440 basis points per deal by leveraging the Velo software and methodology.

Availability
Velo is available now and interested parties can learn more at www.hellovelo.com .

About Profit Velocity Solutions LLC
A San Francisco-based data analytics software company, Profit Velocity has pioneered the use of time-based profit data analytics that enable the management teams of large manufacturers to fine-tune their mix of customers and products and unlock significant investor gains. With its unique profit data visualizations and instant what-if planning, Profit Velocity’s profit information platform turns readily available data into potent new insights that allow decision-makers to isolate and capture gains previously buried in an ocean of corporate data. Profit Velocity has served manufacturers, large and small, across North America, Asia, and Europe. For more information, please visit www.profitvelocity.com .

About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye